Loading...
•
Mar 31, 2025
Sangamo Q1 2025 Earnings Report
Sangamo narrowed its losses and boosted revenue in Q1 2025 through licensing income and lower operating expenses.
Key Takeaways
Sangamo Therapeutics reported $6.4 million in revenue for Q1 2025, significantly up from the prior year due to license and collaboration fees, while cutting its net loss to $30.6 million on reduced operating costs.
Revenue rose to $6.4 million from $0.5 million in Q1 2024 due to Pfizer and Sigma-Aldrich agreements.
Net loss decreased to $30.6 million from $49.1 million year-over-year.
Non-GAAP operating expenses were $32.5 million, down from $43.6 million a year earlier.
Cash balance declined to $25.2 million, but additional capital raised post-quarter end extended runway into Q3 2025.
Revenue by Segment
Forward Guidance
Sangamo reiterated its 2025 guidance, with efforts focused on cost control and Fabry BLA preparation.
Positive Outlook
- Expect to submit BLA for Fabry gene therapy in Q1 2026.
- Received $18M from Lilly for capsid license in April 2025.
- Announced $23M equity raise expected to close mid-May 2025.
- Pivotal data for Fabry program expected by Q2 2025.
- Neurology-focused programs progressing toward clinical milestones.
Challenges Ahead
- Cash only sufficient into Q3 2025, with ongoing need for capital.
- No commercialization partner yet secured for Fabry program.
- Operations require additional funding to continue beyond Q3.
- Stockholder equity fell sharply to $4.9 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...